The global AI Bioreactor Controls Market is forecast to grow from USD 620 million in 2026 to USD 4,529 million by 2036 at a 22.0% CAGR, after crossing USD 508.2 million in 2025, according to Fact.MR.

The market is expanding as biopharma plants, contract development and manufacturing organizations (CDMOs), and food fermentation operators seek tighter control of yield, batch consistency, feed timing, and process deviations. AI-enabled systems can connect real-time process data with recommendations or automated responses for feed, gas, temperature, pH, contamination detection, and yield prediction.

Get detailed market forecasts, competitive benchmarking, and pricing trends:  https://www.factmr.com/connectus/sample?flag=S&rep_id=16139 

Why the Market Is Growing

Biopharma process teams increasingly need control systems that can support validated production while reducing manual intervention. The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research reported 46 novel drug approvals in 2025, creating continued demand for advanced manufacturing and process-development capabilities.

The National Science Foundation announced on August 28, 2025, an investment of $32.4 million across four teams to accelerate cell-free systems and new biotechnology applications. In the UK, the Office for Life Sciences reported 163,600 biopharmaceutical employees in 2023/2024, highlighting the scale of the life-sciences manufacturing base.

External Evidence Supporting Adoption

Several third-party developments reinforce the market opportunity. The FDA CDER reported 46 novel drug approvals in 2025. NSF announced its $32.4 million biotechnology investment in August 2025. The Office for Life Sciences reported 2,960 companies operating in the UK biopharmaceutical subsector in 2023/2024. These developments point to continued investment in biomanufacturing capacity, process data, and digital control infrastructure.

Key Market Numbers

Segment Breakdown

Offering: Control software is expected to hold 38.0% share in 2026. It provides the interface between sensor signals and operating decisions, including recipes, alarms, set points, and exception handling.

Control Function: Feed optimization is projected to account for 50.0% share in 2026. Better nutrient timing can support cell growth, product quality, and batch consistency.

Bioreactor Mode: Fed-batch is anticipated to capture 37.0% share in 2026 because of its broad use in monoclonal antibody and biosimilar production.

End User: Biopharma is estimated to represent 49.0% share in 2026. Biologics manufacturing requires stable pH, dissolved oxygen, feed conditions, and detailed batch records.

Sartorius Stedim Biotech announced on April 9, 2025, that it was working with Tulip Interfaces on Biobrain® Operate, designed to integrate with Sartorius process equipment.

Country Growth Outlook

South Korea leads the profiled country group at 27.4% CAGR, supported by biologics exports and CDMO scale-up. The UK follows at 25.6%, while Germany is projected at 24.4%. Japan is estimated at 23.1%, and the USA at 21.5%.

South Korea’s Ministry of Health and Welfare reported $27.9 billion in biohealth exports in 2025. In the UK, the Office for Life Sciences reported £98.9 billion in biopharmaceutical turnover in 2023/2024. Germany exported €67.9 billion of medicinal and pharmaceutical products to non-EU countries in 2025, according to Eurostat.

Competitive Landscape

Key companies profiled include Sartorius AG, Cytiva, Emerson Electric Co., Siemens AG, Eppendorf SE, and Yokogawa Electric Corporation.

Sartorius participates through Biobrain software, Biostat control platforms, and digital manufacturing applications. Cytiva supports upstream and downstream control through Figurate automation and Xcellerex workflows. Emerson provides DeltaV automation capabilities, while Siemens contributes industrial AI, digital-twin, and automation technologies. Eppendorf supports monitoring and automation through DASware, while Yokogawa’s Bio Pilot integrates bioreactors, PAT instruments, and control systems.

Company-level market shares are not disclosed in the supplied Fact.MR material; therefore, no individual share is assigned to these companies.

Analyst Perspective

Shambhu Nath Jha, Principal Consultant at Fact.MR, states: “Control logic is becoming a quality and yield decision, not only an equipment decision.”

The published commentary also recommends combining bioprocess expertise, PAT integration, and secure plant connectivity as AI control adoption expands.

Frequently Asked Questions

What is the AI Bioreactor Controls Market forecast for 2036?
The market is forecast to reach USD 4,529 million by 2036, up from USD 620 million in 2026.

What is the AI Bioreactor Controls Market CAGR?
The market is projected to expand at a 22.0% CAGR from 2026 to 2036.

Which segment leads the market?
Control software leads the offering segment with a projected 38.0% share in 2026, while feed optimization leads control functions at 50.0%.

Which country has the fastest projected growth?
South Korea is projected to record the highest CAGR among the profiled countries at 27.4%.

Who are the key AI bioreactor controls companies?
Sartorius AG, Cytiva, Emerson Electric Co., Siemens AG, Eppendorf SE, and Yokogawa Electric Corporation are among the key companies profiled.

Top Trending Reports:

https://www.openpr.com/news/4388513/comprehensive-analysis-of-the-autoclaved-aerated-concrete  

https://www.openpr.com/news/4388522/2036-global-oleochemicals-market-intelligence-report   

https://www.openpr.com/news/4388531/aluminum-foil-packaging-market-report-2026-2036-high-value  

https://www.openpr.com/news/4386170/executive-report-future-of-the-global-lacquer-market-key 

About Fact.MR

Fact.MR is a market research and consulting firm providing data-driven intelligence across industries. Its research combines primary interviews, desk research, company analysis, industry data, and market forecasting to support strategic business decisions.